Biohaven Ltd. (BHVN) Stock Price & How to Invest

Biohaven Ltd (NYSE: BHVN) is a clinical-stage biopharmaceutical company developing therapies across neuroscience, immunology, and obesity. It was created in 2022 when Pfizer acquired the original Biohaven's CGRP migraine business (including Nurtec ODT) for roughly $11.6 billion; the remaining non-CGRP pipeline was spun out into the current publicly traded Biohaven Ltd. Its programs include taldefgrobep alfa (a myostatin-activin pathway inhibitor being tested in obesity and spinal muscular atrophy), troriluzole (VYGLXIA, targeted at spinocerebellar ataxia), opakalim (BHV-7000, a Kv7 ion channel activator for focal epilepsy and depression), and MoDE and TRAP extracellular degraders such as BHV-1300 (Graves' disease) and BHV-1400 (IgA nephropathy).

The investment picture is that of a high-risk, catalyst-driven biotech. Biohaven generates little product revenue and funds a large research budget through equity raises, so it burns cash and posts sizable net losses. The FDA issued a Complete Response Letter for troriluzole in spinocerebellar ataxia in late 2025, a setback that shifted market attention to the obesity and epilepsy programs. With multiple pivotal starts and two closely watched topline readouts due in the second half of 2026, the stock tends to move on trial news and financing rather than fundamentals, making runway and data outcomes the central variables.

Biohaven is pre-major-revenue and posts large quarterly net losses, so it depends on repeated equity financing that dilutes existing shareholders. The FDA Complete Response Letter for troriluzole in spinocerebellar ataxia shows regulatory and clinical outcomes can go against the company, and several late-stage readouts in 2026 are binary events that could sharply move the stock in either direction. The obesity field is intensely competitive and dominated by well-capitalized GLP-1 players, and taldefgrobep's muscle-sparing thesis is still unproven in humans at scale. Cash runway relative to a heavy research budget is a persistent concern that investors should monitor.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Biohaven Ltd.'s investor relations page or your broker.

• Market cap: ~$2.3B
• Share price: ~$17
• 52-week range: ~$7.50 to ~$18.60
• Q1 2026 net loss: ~$130M
• Q1 2026 R&D expense: ~$104M
• Cash and equivalents: ~$352M (Q1 2026)

Biohaven trades as a pipeline-value biotech rather than on earnings, with a market cap around $2.3 billion against minimal product revenue and heavy research spending. Q1 2026 saw the net loss narrow to about $130 million from roughly $222 million a year earlier as R&D was trimmed, and the company raised about $179 million through its at-the-market equity program, lifting shares outstanding to roughly 150 million. Cash of about $352 million relative to a nine-figure quarterly burn keeps financing and runway front of mind.

There are three common ways to get BHVN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so BHVN sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where BHVN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Biohaven is a real operating drug developer with a broad pipeline and a binary, catalyst-driven profile, so its story is about upcoming clinical data and cash runway, not present-day earnings.

Whether BHVN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is BHVN a buy?, and where the stock could go from here in the BHVN stock forecast.

For income investors, whether BHVN pays a dividend and how the payout looks is covered in does BHVN pay a dividend?